Page 2 - Protocol Progress News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the s.

United statesNew yorkGaro armenAdvisory incCompany contactProtagenic therapeutics incClinical stageTreatment resistant depressionGeneralized anxiety disorderProtagenic therapeuticsClinical trialProtocol progressGeneralized anxietyMaurizio favaMassachusetts general hospitalPrincipal investigator

Protagenic Therapeutics, Inc : Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics, Inc : Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesDennis riedlProtagenic therapeutics incAdvisory incCompany contactProtagenic therapeuticsProtocol progressTreatment resistant depressionGeneralized anxietyMaurizio favaMassachusetts general hospitalPrincipal investigatorAxiom real time metricsData analyticsCorticotropin releasing factor

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesCompany contactAdvisory incProtagenic therapeutics incProtagenic therapeuticsProtocol progressTreatment resistant depressionGeneralized anxietyMaurizio favaMassachusetts general hospitalPrincipal investigatorAxiom real time metricsData analyticsCorticotropin releasing factorLooking statements

Protagenic Therapeutics (PTIX) Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial

Protagenic Therapeutics (PTIX) Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesProtagenic therapeutics incProtagenic therapeuticsProtocol progressTreatment resistant depressionGeneralized anxietyMaurizio favaMassachusetts general hospitalPrincipal investigatorAxiom real time metricsData analytics

Protagenic Therapeutics (PTIX) Achieves First Clinical Safety Milestone with PT00114

Protagenic Therapeutics (PTIX) Achieves First Clinical Safety Milestone with PT00114
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Protagenic therapeutics incProtagenic therapeuticsProtocol progressTreatment resistant depressionGeneralized anxietyAxiom real time metricsData analyticsMaurizio favaPrincipal investigator